drugset
drugset / Trial / NCT05815290

Cadonilimab in Locally Advanced MSI-H/dMMR Colorectal Cancer

NCT05815290 ↗

Phase 2 Unknown 50 enrolled Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is a two-arm phase II clinical study to evaluate the efficacy and safety of Cadonilimab (a PD-1/CTLA-4 bispecific antibody) in MSI-H/dMMR locally advanced colorectal cancer as the regimen of neoadjuvant treatment. Eligible patients will receive Cadonilimab monotherapy for eight cycles before surgery and part of patients may exempt from surgery.

Timeline

Start
2023-03-29
Primary completion
2024-09-30
Completion
2026-03-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Cadonilimab Monoclonal antibody 10 mg/kg —

Indications

colorectal cancer